Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
Globenewswire·2026-03-25 11:30
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that it has selected Novotech as the contract research organization (“CRO”) for the Company’s upcoming Phase I for its lead drug candidate MB-204. Novotech is an international ...